The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up results of a phase II study of dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).
 
Kana Miyazaki
Honoraria - AstraZeneca; Celgene; Chugai Pharma; Eisai; Janssen; Kyowa Hakko Kirin; Nippon Shinyaku; SymBio Pharmaceuticals; Takeda
Research Funding - Astellas Pharma (Inst); Kyowa Kirin (Inst)
 
Rika Sakai
Honoraria - Celgene; Chugai Pharma; Eisai; Janssen; Kyowa Kirin; Mundipharma; Nippon Shinyaku; Ono Pharmaceutical; Otsuka; Takeda
Research Funding - Chugai Pharma (Inst); Kyowa Kirin (Inst); Taiho Pharmaceutical (Inst)
 
Noriko Iwaki
No Relationships to Disclose
 
Go Yamamoto
Honoraria - Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Kyowa Kirin; Novartis; Ono Pharmaceutical; Sanofi; Takeda
Research Funding - Chugai Pharma
 
Tomomi Yamada
No Relationships to Disclose
 
Yuki Nishimura
No Relationships to Disclose
 
Satoshi Tamaru
No Relationships to Disclose
 
Naoko Asano
Honoraria - Takeda
 
Kohta Miyawaki
No Relationships to Disclose
 
Koji Izutsu
Honoraria - Abbvie; Allergan; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; HUYA Bioscience International; Janssen; Janssen; Kyowa Kirin; MSD; Mundipharma; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Celgene; Kyowa Kirin; Ono Pharmaceutical
Research Funding - Chugai Pharma; Eisai
 
Tomohiro Kinoshita
No Relationships to Disclose
 
Ritsuro Suzuki
Honoraria - Abbvie; Bristol-Myers Squibb; Celgene; Chugai Pharma; Eisai; Janssen; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Otsuka; Takeda
 
Koichi Ohshima
No Relationships to Disclose
 
Koji Kato
Honoraria - Bristol-Myers Squibb; Celgene; Dainippon-Sumitomo; Janssen; Kyowa Kirin International; MSD; Mundipharma; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Novartis
Research Funding - Abbvie; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Kyowa Kirin International; Novartis; Novartis; Ono Pharmaceutical; Takeda
 
Naoyuki Katayama
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Kyowa Kirin; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Shionogi; Sumitomo Group; Takeda
Research Funding - Astellas Pharma (Inst); Kyowa Kirin (Inst)
 
Motoko Yamaguchi
Honoraria - Celgene; Chugai Pharma; Eisai; Janssen; Kyowa Kirin International; MSD; Ono Pharmaceutical; Sumitomo Group
Research Funding - Astellas Pharma (Inst); Chugai Pharma; Kyowa Kirin (Inst)